Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 75   

Articles published

ARNA 3.98 +0.06 (1.53%)
price chart
Why Arena Pharmaceuticals, Inc. Stock Crashed By 31% in 2014
Since the year began, the SPDR S&P Biotech ETF has soared 22%. By comparison, shareholders in Arena Pharmaceuticals (NASDAQ: ARNA ) have endured a multi-month downtrend, with their stock down 31% year-to-date and underperforming the biotech ...
Arena Pharmaceuticals - A Biotech Value Investment  Seeking Alpha (registration)
Investor's Watch List �Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Image ...  Techsonian (press release)
Related articles »  
Arena Down On The Back Of Weigh-Loss Drug Failure
However, Arena Pharmaceuticals Inc. (ARNA) seems to be moving in the opposite direction and has declined 31.6%. Arena has been unable to deliver on expectations of its weight-loss drug, Belviq.
FDA panel backs Novo Nordisk injection  NEWS.com.au
Related articles »  
Surprising New Competitor: Should Arena Pharmaceuticals, Inc. and Orexigen ...
Arena Pharmaceuticals (NASDAQ: ARNA ) and Orexigen's (NASDAQ: OREX ) novel anti-obesity pills are among three drugs that the FDA has approved for use alongside diet and exercise to promote weight loss.
New anti-obesity drug is OK'd  Nashua Telegraph
Could new weight-loss drug Contrave be a weapon in obesity battle?  WRCB-TV
Related articles »  
Arena Pharmaceuticals Short Interest Down 5.7% in August (ARNA)
The company's quarterly revenue was down 81.4% on a year-over-year basis. On average, analysts predict that Arena Pharmaceuticals will post $-0.32 earnings per share for the current fiscal year.
Related articles »  
Orexigen Therapeutics Stumbles Off the Edge of a Cliff (ARNA, VVUS, OREX)
On the off chance you need a reminder, Orexigen Therapeutics, Inc. was greatly ballyhooed heading into last week's decision day from the Food and Drug Administration.
Orexigen Therapeutics, Inc. (NASDAQ:OREX) Obesity Pill Approval Fails to ...  BasicsMedia
Orexigen Therapeutics Wins Contrave Approval But Investors Should Stay Away  Seeking Alpha (registration)
Related articles »  
Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax ...
Investor-Edge has initiated coverage on the following equities: Exelixis Inc. EXEL, -6.90% Arena Pharmaceuticals Inc. ARNA, +0.26% Novavax Inc. NVAX, -0.44% Dendreon Corporation DNDN, -3.29% and Amicus Therapeutics Inc. FOLD, -0.89% Free ...
Related articles »  
On The Watch-List: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Miller Energy ...
Dallas, Texas 09/11/2014 (ustradevoice) - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Eisai will discuss the data from BELVIQ's Phase 3 clinical trial at an event in Austin, Texas.
Worth Watching Stocks �Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...  Techsonian (press release)
Related articles »  
Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary ...
SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. ARNA, +0.26% today announced that the US Food and Drug Administration (FDA) has granted orphan drug status to APD811 for the treatment of pulmonary arterial hypertension.
Arena Pharmaceuticals' APD811 Gets Orphan Drug Status - Analyst Blog  NASDAQ
Related articles »  
Rebounding Stocks: Arena Pharmaceuticals, Inc.(NASDAQ:ARNA), KiOr Inc ...
Arena Pharmaceuticals, Inc.(NASDAQ:ARNA) traded for as little as $3.82 today, a new 52 week low for the company. However, the company's closing price reflected an eight cent boost from the figure recorded on Sept.
Hot Watch List: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Galena ...
On 4 September Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) said that stock analysts at Credit Suisse assumed coverage on shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in a report issued on Thursday. The firm set an �underperform� rating on ...
Related articles »